Cardiogenic Shock

This page includes content on technologies to treat cardiogenic shock, including percutaneous ventricular assist devices (pVAD), intra-aortic balloon pumps (IABP) and extracorporeal membrane oxygenation (ECMO). This condition occurs when the heart can no longer pump enough oxygenated blood to the body. The most common cause of cardiogenic shock is damage to the heart from a severe heart attack. The standard of care for this condition for more than 20 years has a 50 percent survival rate, but improvements have recently been seen in studies using early pVAD intervention prior to percutaneous coronary intervention (PCI). For more information, visit the National Institute of Health (NIH) cardiogenic shock information page

News | Cardiogenic Shock

April 28, 2023 — Windtree Therapeutics, Inc. is a biotechnology company focused on advancing late-stage interventions ...

Home April 28, 2023
Home
News | Cardiogenic Shock

March 22, 2023 — Windtree Therapeutics, Inc., a biotechnology company focused on advancing multiple late-stage ...

Home March 22, 2023
Home
News | Cardiogenic Shock

March 15, 2023 — Windtree Therapeutics, Inc, a biotechnology company focused on advancing late-stage interventions for ...

Home March 15, 2023
Home
News | AHA

November 7, 2022 — The immediate use of veno-arterial mechanical circulatory extracorporeal membrane oxygenation (ECMO) ...

Home November 07, 2022
Home
News | Cardiogenic Shock

October 21, 2022 —  Abiomed announced the U.S. Food and Drug Administration (FDA) has accepted and closed the post ...

Home October 21, 2022
Home
News | Cardiogenic Shock

October 20, 2022 — Cardiogenic shock—a life threatening condition when a person’s heart can’t pump enough blood to meet ...

Home October 20, 2022
Home
News | Cardiogenic Shock

September 22, 2022 — Abiomed (ABMD) announces the result of a three-year, investigator-led study of all Impella ...

Home September 22, 2022
Home
News | Cardiogenic Shock

September 19, 2022 —  Supira Medical, Inc., a Shifamed portfolio company focused on developing the next-generation ...

Home September 19, 2022
Home
News | Heart Failure

September 2, 2022 — Acetazolamide added to intravenous loop diuretics decreases congestion within three days in patients ...

Home September 02, 2022
Home
News | Cardiogenic Shock

June 1, 2022 — Recardio's Phase 2 trial results demonstrated the excellent safety profile of its lead drug Dutogliptin ...

Home June 01, 2022
Home
The global cardiogenic shock market was valued at US$ 3.29 Bn in 2021, and is expected to reach US$ 6.32 Bn by 2032, expanding at a CAGR of 6.2% over the 2022-2032 time frame.
Feature | Cardiogenic Shock

The global cardiogenic shock market was valued at US$ 3.29 Bn in 2021, and is expected to reach US$ 6.32 Bn by 2032 ...

Home May 12, 2022
Home
News | Pharmaceuticals

March 31, 2022 – Windtree Therapeutics, a biotechnology company focused on advancing multiple late-stage interventions ...

Home March 31, 2022
Home
Subscribe Now